Oppenheimer Downgrades Catalyst Pharmaceutical Partners (CPRX) to Perform
Oppenheimer analyst Leland Gershell downgraded Catalyst Pharmaceutical Partners (NASDAQ: CPRX) from Outperform to Perform.
For an analyst ratings summary and ratings history on Catalyst Pharmaceutical Partners click here. For more ratings news on Catalyst Pharmaceutical Partners click here.
Shares of Catalyst Pharmaceutical Partners closed at $30.52 yesterday.